Evidence map›Paper›PMID 28242758›Full record

ArticleThe Journal of biological chemistry2017

CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.

Xin Jin, Chong Yang, Ping Fan, Jun Xiao, Wanli Zhang, Sudong Zhan, Tao Liu, Dejie Wang, Heshui Wu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 103 citations in OpenAlex.

  1. CDK5 targets p21Molecular medicine reports · 2025
    Article
  2. CDK5: Insights into its roles in diseases.Molecular biology reports · 2025
    Review
  3. Article
  4. Molecular insights and clinical implications for the tumor suppressor role of SCFBiochimica et biophysica acta. Reviews on cancer · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Comprehensive analysis of CDK5 as a novel biomarker for progression in esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Xin JinFrom the Departments of Digestive Surgical Oncology and.
Chong Yangthe Organ Transplantation Center, Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China, and.
Ping FanFrom the Departments of Digestive Surgical Oncology and.
Jun XiaoFrom the Departments of Digestive Surgical Oncology and.
Wanli ZhangFrom the Departments of Digestive Surgical Oncology and.
Sudong ZhanFrom the Departments of Digestive Surgical Oncology and.
Tao LiuFrom the Departments of Digestive Surgical Oncology and.
Dejie Wangthe Department of Gastroenterology, Jiangxi Institute of Gastroenterology and Hepatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China wdj5257@sina.com.
Heshui WuPancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China, heshuiwu@163.com.
Union Hospital · CNHuazhong University of Science and Technology · CNNanchang University · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is one of the most lethal cancer types. Enhancer of zeste homolog 2 (EZH2) is an oncogenic protein overexpressed in pancreatic cancer, and EZH2 could be a potential therapeutic target for the treatment of pancreatic cancer. Although significant progress has been made toward understanding the function and deregulation of EZH2 in cancer cells, the posttranslational regulation of EZH2 in cancer cells is still unclear. F-box and WD repeat domain-containing 7 (FBW7) acts as a tumor suppressor by targeting multiple oncoprotein substrates for ubiquitination and degradation. Here we demonstrate that EZH2 is a

Indexed as

Cell MovementProteolysisUbiquitinationCell Cycle ProteinsCell Line, TumorCyclin-Dependent Kinase 5Enhancer of Zeste Homolog 2 ProteinF-Box ProteinsF-Box-WD Repeat-Containing Protein 7HumansNeoplasm InvasivenessNeoplasm ProteinsPancreatic NeoplasmsUbiquitin-Protein LigasesCDK5 protein, humanCell Cycle ProteinsCyclin-Dependent Kinase 5Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanNeoplasm ProteinsUbiquitin-Protein Ligasescell invasioncell migrationE3 ubiquitin ligasepancreatic cancerubiquitylation (ubiquitination)

Identifiers

PMID28242758
PMCPMC5391756
OpenAlexW2592480134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.